RU 486 et sulprostone dans le cadre des interruptions medicales de la grossesse aux 2e et 3e trimestres. [RU 486 and sulprostone in pregnancy termination in the 2nd and 3rd trimesters]

Details

Serval ID
serval:BIB_97E2F1A7DD05
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
RU 486 et sulprostone dans le cadre des interruptions medicales de la grossesse aux 2e et 3e trimestres. [RU 486 and sulprostone in pregnancy termination in the 2nd and 3rd trimesters]
Journal
Journal de Gynécologie, Obstétrique et Biologie de la Reproduction
Author(s)
Werner, H., Jr. , Hohlfeld  P., Jacquemard  F., Mirlesse  V., Menez  D., Daffos  F.
ISSN
0368-2315 (Print)
Publication state
Published
Issued date
1994
Volume
23
Number
6
Pages
701-5
Notes
Clinical Trial
English Abstract
Journal Article
Review
Abstract
OBJECTIVE. Describe our experience with the RU 486 (mifepristone) in case of pregnancy termination induced by sulprostone. METHOD. Prospective non controlled study in the department of Fetal Medicine of the "Institut de Puericulture de Paris". 158 women undergoing termination of pregnancy during the second and third trimester received a single dose of 600 mg of RU 486, 36 hours prior to infusion of 100 micrograms/hour of sulprostone. MAIN OUTCOME MEASURES. Delay between sulprostone therapy and diagnosis of labour duration of delivery. Prostaglandin doses used and frequency of secondary effects. RESULTS. The mean time between sulprostone administration and diagnosis of labour (146.5 +/- 106 minutes) as well delay of delivery (592.2 +/- 504 minutes) corresponded to the results reported in the literature. The primigravid women needed higher doses of prostaglandin and consequently experienced more secondary effects. No severe secondary effects were observed in this study. CONCLUSION. RU 486 is a satisfactory treatment for pregnancy termination during the second or third trimester.
Keywords
Abortifacient Agents, Nonsteroidal/*therapeutic use Abortion, Therapeutic/*methods Adult Clinical Protocols Dinoprostone/*analogs & derivatives/therapeutic use Drug Therapy, Combination Female Humans Middle Aged Mifepristone/*therapeutic use Parity Pregnancy Pregnancy Trimester, Second Pregnancy Trimester, Third Prospective Studies Time Factors
Pubmed
Create date
25/01/2008 12:12
Last modification date
20/08/2019 15:59
Usage data